The art of talking about risks with our patients https://t.co/V0JQ1EsbKc https://t.co/GSTbPu0EXZ

• The art of talking about risks with our patients | RheumNow

Having said that, the EMA warning has elements making it extremely tough: - still very broad criteria that capture 80% of people who were starting JAKi - the need for "no suitable treatment alternatives" before using a JAKi, right across all diseases (not just RA) 3/ #EULAR2024 https://t.co/IsrYO7qzqM

• https://twitter.com/drdavidliew/status/1801144544035225737/photo/1
• https://twitter.com/drdavidliew/status/1801144544035225737/photo/1
• https://twitter.com/drdavidliew/status/1801144544035225737/photo/1

TYK2i RCT 290 pts 12 wks in active PSA TAK-279 15mg 30 mg 53% 54% vs PBO 29% ACR 50 15mg 30 mg 26% 26% vs. PBO 10%response PASI 75 30 mg 46% vs. 15m 28% PBO 15% Safety profile acceptable Abstr#OP0138 #EULAR2024 @RheumNow https://t.co/thNuwvUgQp

• https://twitter.com/AurelieRheumo/status/1801228048466870716/photo/1

I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial. Would love to eventually see: - H2H comparative effect vs toci, secukinumab - structural outcomes - long-term safety #EULAR2024 PBA0001 @RheumNow https://t.co/pHZgCKsoA9 https://t.co/5BxCkkLPti

• https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
• https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
• https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
• https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
• https://twitter.com/drdavidliew/status/1801196482995101974

OP0181- What are the best drugs to treat D2T RA? In this cohort of 185 pts, switching biologic or JAKi improved disease activity & was considered to be effective for patients with D2TRA, regardless of mode of action @RheumNow #EULAR2024

#EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) @RheumNow #EULARBEST https://t.co/ArAzdLYiYY

• https://twitter.com/Yuz6Yusof/status/1801129647603658984/photo/1
• https://twitter.com/Yuz6Yusof/status/1801129647603658984/photo/1

OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs >1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs @RheumNow #EULAR2024

Top 3 messages Re #JAKi #safety Shared decision w benefit/risk info Some #CV risks are more Impt than others- stratify your pt into risk categories #Smoking is a big risk for #MACE & #malignancy-So work on facilitating Smoking #cessation #EULAR2024 @eular_org @RheumNow

OP0072 @RheumNow #EULAR2024 Effects of #Upadacitinib or #Adalimumab on pain in #RA SELECT-COMPARE Phase 3 study UPA & ADA led to improvements in pain vs PBO PtGA & TJC28 pain improvement similar between UPA & ADA ➡️ UPA may be more effective in control of pain than ADA in RA

#Vaccinations against #herpes #zoster in #MTX +#Upadacitinib Pts ▶️ #Shingrix works 👍Pts followed to 60 months #EULAR2024 @eular_org @RheumNow #OP0020 https://t.co/8ORC3Nd2FK

• https://twitter.com/drdavidliew/status/1800906791502647424

OP0086 #EULAR2024 @RheumNow #EULARBest Pain & remission/low disease activity at 3m in pts with #RA in RA-BE-REAL Pts taking #baricitinib more likely to achieve pain control vs TNFi/other mode of action 1/2 pts achieving remission/LDA & had bari achieved ≥70% pain relief.